GlassScriptPhysician profile
Narissa Kourinos
NPI 1356018188
$3,108.07
in general payments reported to CMS, 2019-2025
21 companies · $3,108 in 2025
The $3,108 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,008 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $809.89 | 2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $615.89 | 2025 | Dupixent |
| Genzyme Corporation | $398.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $244.36 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $143.12 | 2025 | Neffy |
| Csl Behring | $137.52 | 2025 | Haegarda, Andembry |
| Amgen INC. | $134.64 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $105.72 | 2025 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Ionis Pharmaceuticals, INC. | $73.80 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $55.54 | 2025 | Orladeyo |
| Paratek Pharmaceuticals, INC. | $47.19 | 2025 | Xhance |
| Blueprint Medicines Corporation | $42.96 | 2025 | Ayvakit |
| Invivyd INC | $42.41 | 2025 | Pemgarda |
| Pfizer INC. | $29.38 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.42 | 2025 | Takhzyro |
| Kedrion Biopharma, INC. | $24.25 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Verona Pharma, INC. | $23.99 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $19.02 | 2025 | Xolair |
| Merck Sharp & Dohme LLC | $18.82 | 2025 | Capvaxive |
| Lilly USA, LLC | $16.29 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narissa Kourinos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.